Elevated Blood Pressure Among Military Emergency Department Patients
Abstract
INTRODUCTION: Hypertension is a leading modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD) resulting in a significant burden on public health. Although the relationship between elevated blood pressure (BP) and long-term ASCVD risk is well-established in older adults, data for younger populations, such as military service members and athletes, remain limited. To assess early detection of hypertension, this study describes the prevalence of elevated BP in emergency departments (EDs) and its relationship with subsequent diagnoses of hypertension.
MATERIALS AND METHODS: A retrospective analysis was conducted using out-patient medical encounters involving active duty U.S. Armed Forces service members between January 2016 and December 2022 (N = 58,426). Sociodemographic and occupational data were obtained from administrative records and electronic health records provided medical data. Multivariable mixed-effects regression analysis was used to assess the relationship between patient characteristics and BP.
RESULTS: The prevalence of hypertension for our sample population presenting to military EDs was 37.9%, though only 3.4% had a prior diagnosis of hypertension. At the time of the ED visit, 30.2% of patients met the criteria for Stage 1 hypertension. During follow-up over the next 12 months, 41.7% remained at Stage 1 or Stage 2 hypertension, with the diagnosis of hypertension rising from 2.5% to 5.7%. Additionally, 7.7% of patients met the criteria for…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 58,426 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.